Latest Conference Articles

Lurbinectedin Plus Irinotecan Is Safe, Prolongs Responses in High-Risk, Pretreated SCLC

Clinical benefit generated from treatment with lurbinectedin plus irinotecan was noted across sensitive and resistant patient populations with SCLC.

Axi-Cel Shows Safety, Clinical Activity in R/R Primary and Secondary CNS Lymphomas

Axi-cel administration was safe and clinically active in relapsed/refractory primary and secondary central nervous system lymphoma.

Amphiphile Lymph Node–Targeted Vaccine Is Safe and Bolsters T-Cell Responses in MRD+ PDAC and CRC

The strength of mKRAS-specific T-cell responses produced by ELI-002 7P correlated with tumor biomarker responses in pancreatic and colorectal cancer.

JNJ-6420 Elicits Responses in mCRPC, But Safety Concerns Arise

A novel radioligand therapy, JNJ-6420, demonstrates potential in treating mCRPCr, delivering sustained responses following only 1-2 doses.

ARV-766 Demonstrates Clinical Activity in AR LBD–Mutated Metastatic CRPC

The investigational PROTAC AR degrader ARV-766 showed promising clinical activity and tolerability in patients with metastatic castration-resistant prostate cancer.

MammaPrint High 2 Indication Could Be Predictive Biomarker for Immunotherapy in HR+/HER2– Early Breast Cancer

MammaPrint high 2 HR-positive/HER2-negative early-stage breast cancer exhibited a heightened immune active state.

Linvoseltamab Generates Efficacy Similar to That Seen With Teclistamab in R/R Myeloma

Linvoseltamab elicited outcomes equivalent to those seen with teclistamab in patients with triple-class exposed relapsed/refractory multiple myeloma.

Dostarlimab With Carboplatin/Paclitaxel Shows Survival Benefits in dMMR/MSI-H Endometrial Cancer

Dostarlimab plus carboplatin and paclitaxel improved PFS and OS in dMMR/MSI-H primary advanced or recurrent endometrial cancer.

Pembrolizumab With Platinum-Based Therapy is Safe and Efficacious in PSCC

Pembrolizumab and platinum-based therapy elicited safe and efficacious outcomes in penile squamous cell carcinoma.

Dr Hughes on Efficacy Data for Asciminib in Newly Diagnosed Ph+ CP-CML

Nivolumab/Cabozantinib Combination Prolongs Treatment-Free Survival in Advanced RCC

Partition overall survival data indicated that nivolumab plus cabozantinib extended treatment-free survival vs sunitinib in advanced renal cell carcinoma.

High CR Rate in NMIBC Is Maintained by Cretostimogene Grenadenorepvec Plus Pembrolizumab

Cretostimogene grenadenorepvec plus pembrolizumab sustains high CR rate in NMIBC according to the phase 2 CORE-001 trial.

Intensification With Apalutamide/ADT Improves PSA PFS in Biochemically Recurrent Prostate Cancer

Apalutamide/ADT maintains quality of life, demonstrates improved PSA progression-free survival in recurrent prostate cancer according to PRESTO trial.

Second-Line T-DXd Data Remain Strong in HER2+ Metastatic Breast Cancer

Trastuzumab deruxtecan improved responses and survival vs T-DM1 in HER2+ metastatic breast cancer after prior exposure to trastuzumab and a taxane.

Daratumumab Retreatment Leads to Responses in Relapsed/Refractory Myeloma

Retreatment with daratumumab-based regimens led to a similar ORR vs initial daratumumab treatment in relapsed/refractory myeloma.

Enzalutamide Treatment Suspension Has No Significant Impact on QOL in nmHSPC

Treatment cessation of enzalutamide-containing regimens in responding patients had no impact on QOL in biochemically recurrent nmHSPC.

Updated Analysis From MajesTEC-1 Confirms CRS Reduction With Prophylactic Tocilizumab in Relapsed/Refractory Myeloma

Dr Garrido-Castro on Sacituzumab Govitecan With or Without Pembrolizumab in Metastatic HR+/HER2– Breast Cancer

Ana Christina Garrido-Castro, MD, on sacituzumab govitecan with/without pembrolizumab in metastatic hormone receptor–positive, HER2-negative breast cancer.

Olverembatinib Demonstrates Early Activity, Tolerability in SDH-deficient GIST

Olverembatinib showed antitumor activity in patients with TKI-resistant, SDH-deficient GISTs and paraganglioma.

TTFields Plus BSC Prolongs Time to Intracranial Progression in NSCLC Brain Metastases

TTFields therapy plus best supportive care increased time to first intracranial progression by 10.6 months in patients with NSCLC brain metastases.

Dr Eads on Nivolumab Plus Neoadjuvant Chemoradiation in Esophageal/GEJ Cancer

Jennifer R. Eads, MD, discusses neoadjuvant pCR rates with the addition of nivolumab to neoadjuvant chemoradiation in esophageal/GEJ cancer.

Dr Classe on Lymphadenectomy Omission in Advanced Epithelial Ovarian Cancer

Jean-Marc Classe, MD, PhD, discusses lymphadenectomy omission following cytoreductive surgery after chemotherapy in advanced epithelial ovarian cancer.

Frontline Petosemtamab Doublet Elicits Responses in Recurrent/Metastatic HNSCC

Petosemtamab paired with pembrolizumab had early clinical efficacy when used as first-line treatment in select head and neck squamous cell carcinoma

Nivolumab Plus Ipilimumab and Chemo Maintains OS Benefit in NSCLC

Nivolumab plus ipilimumab and chemotherapy elicited a durable, long-term survival benefit vs chemotherapy alone in metastatic NSCLC.

CAN-2409 Plus Valacyclovir Shows Favorable Tolerability, Induces Immune Responses in NSCLC

Dr McGregor on the DAD-IO Trial in Treatment-Naive Metastatic Urothelial Carcinoma

Bradley McGregor, MD, discusses the DAD-IO trial of sacituzumab govitecan, enfortumab vedotin, and pembrolizumab in metastatic urothelial cancer.

D-VRd Boosts MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

Daratumumab plus VRd increased rates of MRD negativity in newly diagnosed, transplant-eligible multiple myeloma.

Avelumab Plus Cisplatin-Based Chemotherapy Yields High EFS and OS Rates in MIUC

The addition of avelumab to cisplatin-based chemotherapy led to high event-free survival and overall survival rates in patients with muscle-invasive urothelial carcinoma.

Isa-VRd Prolongs PFS in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

Isatuximab plus VRd produced a statistically significant improvement in PFS vs VRd in newly diagnosed, transplant-ineligible multiple myeloma.

Dostarlimab 2 for 2: Snagging 100% Clinical CR in dMMR Locally Advanced Rectal Cancer

In a phase 2 trial, all 42 patients with locally advanced mismatch repair–deficient rectal cancer achieved clinical complete response with dostarlimab.